NovoBiome (“the Company”), a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome, has been launched today by a team of world-leading experts in the fields of Microbiology and Artificial Intelligence.
The new company will develop breakthrough Live Biotherapeutics Products (LBPs)1 targeting the microbiome-gut-liver axis.
NovoBiome is building a comprehensive, disruptive ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.
NovoBiome’s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). NAFLD has become the most common cause of chronic liver diseases, and can lead to NASH, a more serious condition. Due to the growing epidemic of metabolic disorders with the development of Western lifestyles, the NASH market is rising rapidly and is expected to reach $18.3 billion by 2026
in the US and Europe’s 5 largest markets, a CAGR of 63% from 20162.
The NASH market is seen as the third wave in metabolic diseases, after the rise of obesity and Type 2 diabetes. ADC-001 comprises an anti-inflammatory bacterium, member of the class Coriobacteriia that has demonstrated potent therapeutic effects in vitro and in animal models. It is currently in development with the aim of entering human trials by 2022-2023.
NovoBiome is building a disruptive, ex-vivo research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates. The platform brings together four best-in-class technologies, all of which have separately been nominated “Method of the Year” by Nature Magazine: high-throughput functional metagenomics, human intestinal organoids, high resolution fluorescent
confocal microscopy and a deep learning AI algorithm.
NovoBiome was co-founded by world-leading experts in Microbiome research and AI and is led by Pierre Pierre-Yves Mousset, Chief Executive Officer; Hervé Blottière, Chief Scientific Officer; Olivier Tastet, Chief AI Officer; and Joël Doré, Senior Scientific Consultant.
Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said:
“The microbiome is a fast growing and disruptive field of research that has the potential to revolutionize the diagnosis, prevention and treatment of liver diseases. NovoBiome has been founded to exploit the broad potential of LBPs that target the critical microbiome-gut-liver axis. The role of gut bacteria in the large and growing NAFLD and NASH markets has been clearly documented and NovoBiome aims to provide the first ecosystem treatment approach. With a strong founding team, excellent science, best-in-class technologies and enthusiastic support from investors, we are well positioned to become a leader in discovering next generation gut-liver therapies.”